T. Raber

Predicting the individual probability of macular hole closure following intravitreal ocriplasmin injections for vitreomacular traction release using baseline characteristics

A. Leha, N. Feltgen, T. Bertelmann, 2021, Scientific Reports.

Observational study results in glaucoma patients undergoing a regimen replacement to fixed combination travoprost 0.004%/timolol 0.5% in Germany.

T. Raber, K. Arend, 2008, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Calculating the individual probability of successful ocriplasmin treatment in eyes with vitreomacular traction–Validation and refinement of a multivariable prediction model

T. Bertelmann, T. Raber, C. Paul, 2022, PloS one.

Prognostic Factors Associated with Ocriplasmin Efficacy for the Treatment of Symptomatic Vitreomacular Adhesion and Full-thickness Macular Hole: Analysis from Four Studies

B. Joondeph, L. Duchateau, T. Raber, 2021, Journal of ophthalmic & vision research.

Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice

I. Lanzl, T. Raber, 2011, Clinical ophthalmology.

OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE

N. Patton, D. Steel, H. Hoerauf, 2020, Retina.